IL144847A0 - Combinations for the treatment of diseases involving angiogenesis - Google Patents

Combinations for the treatment of diseases involving angiogenesis

Info

Publication number
IL144847A0
IL144847A0 IL14484700A IL14484700A IL144847A0 IL 144847 A0 IL144847 A0 IL 144847A0 IL 14484700 A IL14484700 A IL 14484700A IL 14484700 A IL14484700 A IL 14484700A IL 144847 A0 IL144847 A0 IL 144847A0
Authority
IL
Israel
Prior art keywords
combinations
treatment
diseases involving
involving angiogenesis
formation
Prior art date
Application number
IL14484700A
Other languages
English (en)
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Publication of IL144847A0 publication Critical patent/IL144847A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
IL14484700A 1999-02-16 2000-02-15 Combinations for the treatment of diseases involving angiogenesis IL144847A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903404.3A GB9903404D0 (en) 1999-02-16 1999-02-16 Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
PCT/GB2000/000511 WO2000048591A1 (fr) 1999-02-16 2000-02-15 Combinaisons pour traiter les maladies faisant intervenir l'angiogenese

Publications (1)

Publication Number Publication Date
IL144847A0 true IL144847A0 (en) 2002-06-30

Family

ID=10847791

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14484700A IL144847A0 (en) 1999-02-16 2000-02-15 Combinations for the treatment of diseases involving angiogenesis
IL144847A IL144847A (en) 1999-02-16 2001-08-09 Compositions for the treatment of diseases related to the formation of blood vessels

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144847A IL144847A (en) 1999-02-16 2001-08-09 Compositions for the treatment of diseases related to the formation of blood vessels

Country Status (21)

Country Link
US (2) US7087627B1 (fr)
EP (1) EP1161235B1 (fr)
JP (1) JP4708569B2 (fr)
KR (2) KR20070034642A (fr)
CN (1) CN1344159B (fr)
AT (1) ATE288264T1 (fr)
AU (1) AU775242B2 (fr)
BR (1) BR0008254A (fr)
CA (1) CA2362281C (fr)
DE (1) DE60017878T2 (fr)
DK (1) DK1161235T3 (fr)
ES (1) ES2237407T3 (fr)
GB (1) GB9903404D0 (fr)
HK (1) HK1040919B (fr)
IL (2) IL144847A0 (fr)
MX (1) MXPA01008245A (fr)
NO (1) NO20013966L (fr)
NZ (1) NZ513429A (fr)
PT (1) PT1161235E (fr)
WO (1) WO2000048591A1 (fr)
ZA (1) ZA200106688B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
WO2002009700A1 (fr) 2000-07-28 2002-02-07 Cancer Research Technology Limited Traitement combine contre le cancer
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US20050153939A1 (en) 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
AU1602902A (en) * 2000-10-27 2002-05-06 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
AU2002246827B2 (en) * 2000-12-22 2008-02-21 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
JP2004536847A (ja) * 2001-07-13 2004-12-09 オキシジーン， インコーポレイテッド 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
AU2008202468B2 (en) * 2001-07-13 2011-08-11 Oxigene, Inc. Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
ATE311228T1 (de) * 2001-08-30 2005-12-15 Cancer Rec Tech Ltd Antikrebs-kombinationen aus dmxaa und paclitaxel oder docetaxel
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2008147445A2 (fr) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Utilisation de l'acide 5,6-diméthylxanthénone-4-acétique en tant qu'agent antimicrobien
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
WO2009067706A1 (fr) 2007-11-21 2009-05-28 Oxigene, Inc. Procédé pour traiter des néoplasmes hématopoïétiques
WO2014089177A2 (fr) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines
EP2972394A4 (fr) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer Imagerie cardiaque à ciblage hsp90 et traitement associé
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
WO2017197045A1 (fr) 2016-05-11 2017-11-16 Movassaghi Mohammad Synthèse totale convergente et énantiosélective d'analogues de la communesine
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670720A1 (fr) 1992-11-27 1995-09-13 The Wellcome Foundation Limited Inhibiteurs enzymatiques
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5424447A (en) * 1993-07-07 1995-06-13 The Medical College Of Wisconsin Research Foundation, Inc. Heme binding compounds and use thereof
GB9320484D0 (en) 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
AU4515896A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1997032585A1 (fr) * 1996-03-05 1997-09-12 Medinox, Inc. Procedes therapeutiques combinatoires utilisant des piegeurs de monoxyde d'azote et compositions utiles dans ces procedes
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

Also Published As

Publication number Publication date
ATE288264T1 (de) 2005-02-15
PT1161235E (pt) 2005-05-31
CA2362281C (fr) 2008-11-18
IL144847A (en) 2006-10-31
EP1161235B1 (fr) 2005-02-02
DE60017878D1 (de) 2005-03-10
CN1344159B (zh) 2011-09-28
NZ513429A (en) 2003-10-31
HK1040919B (en) 2005-05-13
JP4708569B2 (ja) 2011-06-22
WO2000048591A1 (fr) 2000-08-24
NO20013966L (no) 2001-10-15
NO20013966D0 (no) 2001-08-15
CA2362281A1 (fr) 2000-08-24
US7087627B1 (en) 2006-08-08
DK1161235T3 (da) 2005-05-09
AU2559000A (en) 2000-09-04
ZA200106688B (en) 2002-08-14
KR20010102038A (ko) 2001-11-15
ES2237407T3 (es) 2005-08-01
DE60017878T2 (de) 2006-01-26
CN1344159A (zh) 2002-04-10
JP2002537251A (ja) 2002-11-05
EP1161235A1 (fr) 2001-12-12
BR0008254A (pt) 2001-11-06
HK1040919A1 (en) 2002-06-28
KR20070034642A (ko) 2007-03-28
GB9903404D0 (en) 1999-04-07
MXPA01008245A (es) 2002-10-23
AU775242B2 (en) 2004-07-22
US20060198846A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
IL144847A0 (en) Combinations for the treatment of diseases involving angiogenesis
EP1034164A4 (fr) Derives d&#39;alanine-beta agissant en tant qu&#39;inhibiteurs de l&#39;adhesion cellulaire
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
EP1017382A4 (fr) Acide biarylalcanoique utilise en tant qu&#39;inhibiteur de l&#39;adhesion cellulaire
BR9917089A (pt) Composições e métodos para distribuição mucosal
KR960703603A (ko) 프로게스테론형 제제 및 산화질소 합성효소 기질 및 산화질소 공여물질의 배합물을 사용한 자간전증 및 조산의 치료(Combination of a Progestational Agent and a Nitric Oxide Synthase substrate and/or Donor for the Treatment of Preeclampsia and Preterm Labor)
AU2002356759A1 (en) 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
EP1113000A4 (fr) Derives de benzene et leur utilisation medicale
AU2001266575A1 (en) Chemical compounds
NZ513096A (en) Compositions for treating inflammatory response
AU2002213421A1 (en) Condensed pyridoindole derivatives
WO2002070469A3 (fr) Inhibiteurs selectifs de pde3b et leurs utilisations therapeutiques
WO2000040583A3 (fr) Derives d&#39;imidazo[4,5-c]pyridine-4-one
WO2002003978A3 (fr) Combinaison d&#39;inhibiteurs de fbpase et d&#39;agents antidiabetiques utile pour le traitement du diabete
WO2001056555A3 (fr) Utilisation d&#39;inhibiteurs de cox-2 dans le traitement de la constipation
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
CA2412596A1 (fr) Inhibiteurs de phosphodiesterase specifique de gmp cyclique
TWI262794B (en) Catheter composition and uses thereof
MXPA02012472A (es) Compuestos quimicos.
NZ516620A (en) 1,4-substituted 4,4-diaryl cyclohexanes
WO2001097790A3 (fr) Polytherapie anticancereuse a base de derives de distamycine a substitution acryloyle et d&#39;agents alkylants

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed